S
Sarina Anne Piha-Paul
Researcher at University of Texas MD Anderson Cancer Center
Publications - 426
Citations - 19455
Sarina Anne Piha-Paul is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 54, co-authored 363 publications receiving 12582 citations. Previous affiliations of Sarina Anne Piha-Paul include University of Texas at Austin & University College Hospital.
Papers
More filters
Journal ArticleDOI
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers,Jared Lunceford,Michael Nebozhyn,Erin Murphy,Andrey Loboda,David Ross Kaufman,Andrew Albright,Jonathan D. Cheng,S. Peter Kang,Veena Shankaran,Sarina Anne Piha-Paul,Jennifer H. Yearley,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan +14 more
TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle,Marwan Fakih,Juanita Lopez,Manisha H. Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,Hyun Cheol Chung,Hedy L. Kindler,Jose A. Lopez-Martin,Wilson H. Miller,Antoine Italiano,Steven Kao,Sarina Anne Piha-Paul,Jean Pierre Delord,Robert R. McWilliams,David Fabrizio,Deepti Aurora-Garg,Lei Xu,F. Jin,Kevin Norwood,Yung-Jue Bang +20 more
TL;DR: The association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours, was prospectively explored.
Journal ArticleDOI
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Hyun Cheol Chung,Willeke Ros,Jean Pierre Delord,Ruth Perets,Antoine Italiano,Ronnie Shapira-Frommer,Lyudmila Manzuk,Sarina Anne Piha-Paul,Lei Xu,Susan Zeigenfuss,Scott K. Pruitt,Alexandra Leary +11 more
TL;DR: Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer and the US Food and Drug Administration granted accelerated approval of pembrolIZumab for patients withAdvanced PD-L1-positive cervical cancer who experienced progression during or after chemotherapy.
Journal ArticleDOI
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott,Yung-Jue Bang,Sarina Anne Piha-Paul,Albiruni Ryan Abdul Razak,Jaafar Bennouna,Jean-Charles Soria,Hope S. Rugo,Roger B. Cohen,Bert H. O'Neil,Janice M. Mehnert,Juanita Lopez,Toshihiko Doi,Emilie M.J. van Brummelen,Razvan Cristescu,Ping Yang,Kenneth Emancipator,Karen Stein,Mark Ayers,Andrew K. Joe,Jared Lunceford +19 more
TL;DR: Response patterns indicate that patients with tumors that had high levels of both TMB and inflammatory markers (GEP or PD-L1) represent a population with the highest likelihood of response to pembrolizumab in multiple tumor types.